Reslizumab in Eosinophilic Asthma: A Review-Reference-Cited by-同舟云学术

Reslizumab in Eosinophilic Asthma: A Review

Published:2017-04-18 Issue:7 Volume:77 Page:777-784
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Deeks Emma D.,Brusselle Guy

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-017-0740-2.pdf

Reference34 articles.

1. de Groot JC, Ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1(1). doi: 10.1183/23120541.00024-2015 .

2. Patterson MF, Borish L, Kennedy JL. The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review. J Asthma Allergy. 2015;8:125–34.

3. Greenfeder S, Umland SP, Cuss FM, et al. Th2 cytokines and asthma: the role of interleukin-5 in allergic eosinophilic disease. Respir Res. 2001;2(2):71–9.

4. Teva Pharmaceuticals Ltd. Reslizumab (Cinqaero®): summary of product characteristics. 2016. http://www.ema.europa.eu . Accessed 28 Mar 2017.

5. Teva Respiratory LLC. Cinqair® (reslizumab) injection, for intravenous use: US prescribing information. 2016. http://www.cinqair.com . Accessed 28 Mar 2017.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the Terrain: Type 2 Cytokines and Biologic intervention in Severe Eosinophilic Asthma;Eosinophils and Their Role in Human Health and Disease [Working Title];2024-08-23

2. Biologics in Asthma;Immunology and Allergy Clinics of North America;2024-08

3. Role of IL‐5 in asthma and airway remodelling;Clinical & Experimental Allergy;2024-06-27

4. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan;Drugs;2024-06

5. Novel Immunopharmacological Drugs for the Treatment of Allergic Diseases;Annual Review of Pharmacology and Toxicology;2024-01-23